77 results
424B5
RVPH
Reviva Pharmaceuticals Holdings Inc.
28 May 24
Prospectus supplement for primary offering
6:14pm
(OLE) trial evaluating long-term safety and tolerability, and a soon to be initiated registrational global, randomized 4-week Phase 3 RECOVER-2 trial … that it will require a long-term randomized withdrawal study post-approval to support maintenance of effect. Data from these brilaroxazine clinical trials
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 May 24
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
8:10am
announcing an enrollment update to the RECOVER ongoing 1-year open label extension (“OLE”) study evaluating the long-term safety and tolerability … of treatment
Long-term safety data from 100 patients who have completed 12 months of treatment is a requirement for brilaroxazine’s NDA submission
8-K
EX-99.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 May 24
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
8:10am
to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia … to gathering long-term safety data in 100 patients with one year of treatment, which is a requirement for our planned New Drug Application (NDA) submission
8-K
EX-99.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
14 May 24
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
8:12am
, and topline data from our 1-year OLE trial which will inform on the long-term safety and efficacy of brilaroxazine in the fourth quarter of this year …
Indication that two positive Phase 3 studies showing efficacy at week 4 that are accompanied by long-term safety data of at least 12 months could be supportive
8-K
EX-99.1
clao9ffkj2p2
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
8-K
mzmap68ov 7lbe
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
8-K
EX-99.1
f28 pix9b
15 Apr 24
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
8:20am
424B4
oxfxfo4
13 Feb 24
Prospectus supplement with pricing info
5:00pm
424B5
wdvuf
17 Nov 23
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.1
l456mqobpjhx
14 Nov 23
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:12pm
8-K
jd0 q62tm8yqsu
30 Oct 23
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
8:20am
8-K
EX-99.1
xod nhn89sal4qihv
30 Oct 23
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
8:20am
8-K
jsiia5x9 l93
17 Aug 23
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
6:30am
8-K
EX-99.1
aje 79x8ga
17 Aug 23
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
6:30am
8-K
EX-99.1
9o800y0qh 4ol3
23 Jun 23
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
6:30am